We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Moves -0.34%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Moderna (MRNA - Free Report) closed at $103.44, marking a -0.34% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.58% for the day. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 1.15%.
Heading into today, shares of the biotechnology company had lost 1.26% over the past month, outpacing the Medical sector's loss of 6.07% and lagging the S&P 500's loss of 1.09% in that time.
Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. The company is expected to report EPS of -$3.36, down 1868.42% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $238.56 million, down 87.19% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.51 per share and revenue of $4.16 billion, indicating changes of +39.09% and -39.27%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Moderna should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.4% lower. At present, Moderna boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 82, positioning it in the top 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Moves -0.34%: What You Should Know
In the latest trading session, Moderna (MRNA - Free Report) closed at $103.44, marking a -0.34% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.58% for the day. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 1.15%.
Heading into today, shares of the biotechnology company had lost 1.26% over the past month, outpacing the Medical sector's loss of 6.07% and lagging the S&P 500's loss of 1.09% in that time.
Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. The company is expected to report EPS of -$3.36, down 1868.42% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $238.56 million, down 87.19% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.51 per share and revenue of $4.16 billion, indicating changes of +39.09% and -39.27%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Moderna should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.4% lower. At present, Moderna boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 82, positioning it in the top 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.